Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL

Source: 2020 American Society of Hematology Virtual Annual Meeting*
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Listen to Jeremy S. Abramson, MD, MMSc, discuss the presentations from ASH 2020 that he expects to affect practice in the management of patients with lymphomas/CLL.
Jeremy S. Abramson, MD, MMSc
Released: March 26, 2021

In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:

  • Approved and Investigational Targeted Therapeutics for CLL
  • Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell Lymphoma
  • Bispecific Antibodies and Other Investigational Targeted Agents for Lymphomas
  • Treatment for Older Patients With Hodgkin Lymphoma

Presenters:

Jeremy S. Abramson, MD, MMSc
Associate Professor  
Department of Medicine  
Harvard Medical School  
Director, Center for Lymphoma  
Massachusetts General Hospital  
Boston, Massachusetts

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

On-demand webcast from a satellite symposia at the 2021 Hematology meeting on diagnosis and management of aTTP, from Clinical Care Options (CCO)

Ara Metjian, MD
Program Director Paul Coppo, MD, PhD Marshall Mazepa, MD Physicians: maximum of 1.75 AMA PRA Category 1 Credits™ Released: January 26, 2022 Expired: January 25, 2023

Free video from Clinical Care Options (CCO) featuring expert discussion of use of asparaginase-based treatments in young and older adults with acute lymphoblastic leukemia

Wendy Stock, MD
Program Director Emily Curran, MD Dan Douer, MD person default Scott Howard, MD, MSc person default Stephen P. Hunger, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits™ Released: January 24, 2022 Expired: January 23, 2023

In this commentary from Clinical Care Options (CCO), Asim V. Farooq, MD and Joann Kang, MD, provide guidance on monitoring and mitigating ocular toxicities associated with antibody-drug conjugates

Asim V. Farooq, MD Joann Kang, MD Released: January 20, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the diagnosis and staging of light-chain amyloidosis

Shaji K. Kumar, MD Released: January 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings